Natera Inc (NTRA) Stock Price, Quote & News

Company Profile

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provi...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 980 9190

Website: www.natera.com

Address:

13011 McCallen Pass, Building A Suite 100, Austin, United States

JFDI May. 29 at 3:29 PM

$NTRA range expansion

0 · Reply

JasonCO May. 29 at 2:35 PM

$NTRA don’t look back; lfgggg

0 · Reply

MD109 May. 28 at 5:14 PM

$PSNL I’ve said this before, but there is significant hidden value in $PSNL within the cancer vaccine market. The reason Moderna/Merck partnered with Personalis is because they have best in class technology - superior to $NTRA. The success of the vaccine depends in large part on the accuracy of the data Personalis provides to Moderna when building each individualized vaccine. Merck is also a major Personalis shareholder - something the newer investors may not be aware of. So we have 3 major business units that will grow rapidly: Clinical MRD, Biopharma MRD and cancer vaccine development (if approved). Again - this is just the beginning for Personalis and the MRD market is still in early days. Hold your shares tight.

2 · Reply

BillionerOfKing May. 27 at 5:11 PM

$NTRA Current Stock Price: $201.90 Contracts to trade: $200.0 NTRA Jun 18 2026 Call Entry: $10.40 Exit: $15.61 ROI: 50% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

CapitalMonk May. 25 at 11:13 PM

$NTRA Price: $203.19 (-0.25%) Trend: Bearish Market Bias (7D): Sideways ⚖️ Expected Range: ±2.50% RSI: 45.6 | Momentum: Moderate Volume: -39.0% vs avg Volatility: 4.03% Support: $184.81 | Resistance: $221.56 Sourch: http://marketbaubles.com/

0 · Reply

RockyMontana May. 24 at 9:06 AM

$PSNL is not in BTK group, but $NTRA $ILMN $VCYT are. Theme matters in this case. I leave the rest to u.

0 · Reply

Orbit100 May. 22 at 4:35 PM

$NTRA Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World Business Wire 07:00:00 AM ET, 05/21/2026

0 · Reply

Orbit100 May. 22 at 4:09 PM

$NTRA CFRA, LSEG and Market Edge all covered Natera as a strong buy in late April. It is still far from 52 weeks high. I am in 800 shares.

0 · Reply

Merlintrader May. 22 at 3:12 PM

$NTRA Natera, Inc. (Nasdaq: $NTRA): A Full Deep Dive Into the cfDNA Platform, Signatera Momentum, FDA CDx Validation, Fetal Focus, Prospera and the Next Catalyst Stack https://www.merlintrader.com/natera-inc-may2026-deepdive/

0 · Reply

CapitalMonk May. 21 at 11:29 PM

$NTRA Price: $203.69 (-0.60%) Trend: Bearish Market Bias (7D): Sideways ⚖️ Expected Range: ±2.58% RSI: 48.2 | Momentum: Moderate Volume: -12.1% vs avg Volatility: 4.04% Support: $184.81 | Resistance: $221.56 Sourch: http://marketbaubles.com/

0 · Reply

Natera announces collaboration with Diakonos Oncology for Signatera in RM

$Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma$

May 29, 2026, 6:00 AM EDT - 6 hours ago

Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma

2026-05-28T10:25:18.000Z - 1 day ago

Natera enrolls first patients in SIGNAL-ER 101 study

May 28, 2026, 6:00 AM EDT - 1 day ago

Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer

May 26, 2026, 6:00 AM EDT - 3 days ago

Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology

May 21, 2026, 5:05 PM EDT - 7 days ago

Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology

2026-05-21T11:18:39.000Z - 8 days ago

Natera announces expansion into Austin, creating largest sequencing factory

May 21, 2026, 7:00 AM EDT - 8 days ago

Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World

2026-05-20T11:07:32.000Z - 9 days ago

Natera announces Expand trial enrolled over 2,000 patients

May 20, 2026, 7:00 AM EDT - 9 days ago

EXPAND Trial of Natera's Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled

2026-05-15T17:02:31.000Z - 13 days ago

Signatera CDx approved by FDA as companion diagnostic in MIBC

May 15, 2026, 12:45 PM EDT - 13 days ago

Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)

May 14, 2026, 5:30 AM EDT - 15 days ago

The Cancer Test That Wall Street Is Betting On

2026-05-14T01:35:09.000Z - 15 days ago

Cathie Wood’s ARK Investment buys 17.3K shares of Natera today

2026-05-12T11:15:02.000Z - 17 days ago

Natera price target raised to $249 from $240 at Piper Sandler

May 10, 2026, 2:30 PM EDT - 18 days ago

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

EW ISRG LLY NVO

May 8, 2026, 4:08 PM EDT - 20 days ago

Natera Q1 Earnings Call Highlights

2026-05-08T18:12:13.000Z - 20 days ago

Natera price target raised to $270 from $250 at Evercore ISI

2026-05-08T16:24:15.000Z - 20 days ago

Natera price target raised to $265 from $257 at Baird

2026-05-08T13:32:55.000Z - 21 days ago

Natera price target raised to $265 from $260 at JPMorgan

2026-05-08T12:34:01.000Z - 21 days ago

Natera price target raised to $265 from $260 at JPMorgan

2026-05-08T12:23:32.000Z - 21 days ago

Natera price target raised to $220 from $215 at Wells Fargo

2026-05-07T21:22:17.000Z - 21 days ago

Natera reports Q1 EPS -60c, consensus -55c

2026-05-07T21:21:12.000Z - 21 days ago

Natera sees 2026 revenue $2.74B-$2.82B, consensus $2.67B

May 7, 2026, 4:30 PM EDT - 21 days ago

Natera Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 21 days ago

Natera Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 21 days ago

Natera Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 21 days ago

Natera Quarterly report: Q1 2026

May 7, 2026, 4:05 PM EDT - 21 days ago

Natera Reports First Quarter 2026 Financial Results

Apr 30, 2026, 8:00 AM EDT - 4 weeks ago

Natera to Report its First Quarter Results on May 7, 2026

Apr 23, 2026, 8:00 AM EDT - 5 weeks ago

Natera Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 5 weeks ago

Natera Proxy statement: Proxy filing

2026-04-22T13:13:22.000Z - 5 weeks ago

Natera announces evidence for Prospera test at 2026 ISHLT

Apr 22, 2026, 9:00 AM EDT - 5 weeks ago

Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT

2026-04-14T09:00:14.000Z - 6 weeks ago

Natera initiated with an Outperform at William Blair

2026-04-13T12:27:31.000Z - 6 weeks ago

Natera highlights Allogene Therapeutics’ analysis from ALPHA3 trial

ALLO

Apr 13, 2026, 8:00 AM EDT - 6 weeks ago

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

ALLO

2026-04-09T10:06:58.000Z - 7 weeks ago

Natera awarded 30% ongoing royalty for MRD-related patents

Apr 9, 2026, 6:00 AM EDT - 7 weeks ago

Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents

2026-04-07T10:16:39.000Z - 7 weeks ago

Citi opens ‘upside 90-day catalyst watch’ on Natera

Apr 7, 2026, 6:00 AM EDT - 7 weeks ago

20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera's Oncology Platform

Mar 31, 2026, 6:00 AM EDT - 2 months ago

SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery

Mar 16, 2026, 6:00 AM EDT - 2 months ago

Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers

Mar 12, 2026, 8:00 AM EDT - 2 months ago

MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026

Mar 12, 2026, 8:00 AM EDT - 2 months ago

Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis

Mar 10, 2026, 8:00 AM EDT - 2 months ago

Natera Transcript: Leerink Global Healthcare Conference 2026

Mar 4, 2026, 1:05 PM EST - 3 months ago

Natera Transcript: 47th Annual Raymond James Institutional Investor Conference

Feb 27, 2026, 10:05 AM EST - 3 months ago

Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation

Feb 26, 2026, 4:30 PM EST - 3 months ago

Natera Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 3 months ago

Natera Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 3 months ago

Natera Earnings release: Q4 2025

Feb 26, 2026, 4:30 PM EST - 3 months ago

Natera Slides: Q4 2025

Feb 26, 2026, 4:05 PM EST - 3 months ago

Natera Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 24, 2026, 6:00 AM EST - 3 months ago

Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer

Feb 17, 2026, 9:00 AM EST - 3 months ago

Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026

Feb 6, 2026, 6:00 AM EST - 4 months ago

Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

Feb 2, 2026, 6:00 AM EST - 4 months ago

Natera Submits Signatera™ CDx PMA to FDA

Jan 28, 2026, 8:00 AM EST - 4 months ago

Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation

Jan 26, 2026, 6:00 AM EST - 4 months ago

Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care

Jan 21, 2026, 6:00 AM EST - 4 months ago

Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

Jan 20, 2026, 6:00 AM EST - 4 months ago

Natera's Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting

Jan 13, 2026, 7:30 PM EST - 4 months ago

Natera Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 7:30 PM EST - 4 months ago

Natera Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 8:00 AM EST - 4 months ago

Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling

Jan 12, 2026, 10:00 AM EST - 4 months ago

Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA

Jan 11, 2026, 10:48 PM EST - 4 months ago

Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth

Jan 7, 2026, 1:49 PM EST - 5 months ago

Trade Tracker: Stephanie Link sells Eaton and buys more Zoetis, Natera

ZTS ETN

Jan 7, 2026, 8:00 AM EST - 5 months ago

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

EXEL

Jan 5, 2026, 7:25 PM EST - 5 months ago

Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI

Jan 5, 2026, 7:00 AM EST - 5 months ago

Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology

Dec 22, 2025, 8:00 AM EST - 5 months ago

Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:00 AM EST - 5 months ago

Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer

Dec 16, 2025, 8:00 AM EST - 5 months ago

I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer

Dec 12, 2025, 8:00 AM EST - 6 months ago

Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer

Dec 11, 2025, 10:37 AM EST - 6 months ago

Eight stock picks to play one of the healthiest corners of the market

ALNY ASND INSM MASI PODD UNH WGS

Dec 10, 2025, 7:57 PM EST - 6 months ago

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer

Dec 9, 2025, 8:00 AM EST - 6 months ago

Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting

Dec 5, 2025, 7:00 AM EST - 6 months ago

Natera Acquires Foresight Diagnostics

Dec 5, 2025, 7:00 AM EST - 6 months ago

Natera Registration statement: Registration Filing

Dec 3, 2025, 8:00 AM EST - 6 months ago

New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting

Dec 3, 2025, 8:00 AM EST - 6 months ago

Natera Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 8:00 AM EST - 6 months ago

Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium

Nov 19, 2025, 10:00 AM EST - 6 months ago

Natera Transcript: Wolfe Research Healthcare Conference 2025

Nov 19, 2025, 8:00 AM EST - 6 months ago

Employees Volunteer Over 1,500 Hours During Natera's Annual Volunteer Month

Nov 18, 2025, 8:00 AM EST - 6 months ago

Natera Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 8:00 AM EST - 7 months ago

Natera Integrates with Flatiron Health's OncoEMR® Platform

Nov 11, 2025, 11:45 AM EST - 7 months ago

Natera Transcript: UBS Global Healthcare Conference 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

Natera Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

Natera Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

Natera Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

Natera Slides: Q3 2025

Nov 6, 2025, 4:05 PM EST - 7 months ago

Natera Reports Third Quarter 2025 Financial Results

JFDI May. 29 at 3:29 PM

$NTRA range expansion

0 · Reply

JasonCO May. 29 at 2:35 PM

$NTRA don’t look back; lfgggg

0 · Reply

MD109 May. 28 at 5:14 PM

2 · Reply

BillionerOfKing May. 27 at 5:11 PM

0 · Reply

CapitalMonk May. 25 at 11:13 PM

0 · Reply

RockyMontana May. 24 at 9:06 AM

$PSNL is not in BTK group, but $NTRA $ILMN $VCYT are. Theme matters in this case. I leave the rest to u.

0 · Reply

Orbit100 May. 22 at 4:35 PM

$NTRA Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World Business Wire 07:00:00 AM ET, 05/21/2026

0 · Reply

Orbit100 May. 22 at 4:09 PM

$NTRA CFRA, LSEG and Market Edge all covered Natera as a strong buy in late April. It is still far from 52 weeks high. I am in 800 shares.

0 · Reply

Merlintrader May. 22 at 3:12 PM

0 · Reply

CapitalMonk May. 21 at 11:29 PM

0 · Reply

JasonCO May. 20 at 2:18 PM

$NTRA we back

0 · Reply

GordoHLYK13 May. 20 at 12:13 PM

$NEO Back in 2018 I held 1k shares of NeoGenomics at a $13 average and watched it run to $60. Fast forward to 2026… now I’m holding 4k shares at $8.56 and the setup honestly looks even stronger. NEO today isn’t the same company from 2018 — bigger revenue, deeper oncology relationships, more advanced molecular testing, AI-driven diagnostics, and expanding precision medicine exposure. While everyone chases hype, NEO is quietly building a real cancer diagnostics powerhouse. The business is making substantially more money than it was during the last major run, yet the stock trades at a fraction of those levels. If execution keeps improving and margins expand, this could easily feel like NeoGenomics 4.0. 🚀 $NEO making way more money than the 2018 run to $60… yet trading near $8. Different beast now — stronger tech, bigger oncology footprint, AI diagnostics growth, and huge upside if sentiment flips. NeoGenomics 4.0 loading. 🔥 $TEM $NTRA $GH $EXAS

1 · Reply

Orbit100 May. 19 at 5:27 PM

$NTRA Purchased 800 shares yesterday as it flashed a buy signal even after it jumped. Far from its 52 weeks high. Cathie Wood keeps loading up this stock like she can't have enough shares of it.

0 · Reply

GordoHLYK13 May. 17 at 2:22 PM

$NEO NeoGenomics isn’t just another lab company — it’s deeply embedded into the entire Southwest Florida oncology ecosystem. From Lee Health to Millennium Physician Group and Florida Cancer Specialists & Research Institute, major cancer networks rely on NeoGenomics’ advanced genetic testing to guide precision treatments, immunotherapy, and clinical trial decisions. $NEO is becoming the “brains behind cancer treatment” in Southwest Florida — every biopsy, sequencing panel, and precision therapy decision strengthens their moat, recurring revenue, and role in the future of personalized oncology. $IBRX $NTRA $SLS $HCWB

4 · Reply

Joker83 May. 17 at 11:19 AM

$MDXH $GH $NTRA $PSNL $MDXH

0 · Reply

Joker83 May. 17 at 11:18 AM

$MDXH $GH $NTRA $PSNL $MDXH

0 · Reply

WantedToRetireEarly May. 17 at 10:40 AM

$NTRA $IBRX

1 · Reply

Jaxtyn1989 May. 15 at 7:40 PM

$MDXH like a said, just some volume can push it to $1 and then $1.5 and all the way to $3 could be possible! $GH $NTRA $PSNL check out $MDXH

0 · Reply

invisiblesurfer May. 15 at 6:21 PM

$NTRA FDA approval https://www.natera.com/company/news/signatera-cdx-approved-by-the-fda-as-a-companion-diagnostic-in-muscle-invasive-bladder-cancer-mibc/

0 · Reply

S_Franconi May. 15 at 5:35 PM

$NTRA https://investor.natera.com/news/news-details/2026/Signatera-CDx-Approved-by-the-FDA-as-a-Companion-Diagnostic-in-Muscle-Invasive-Bladder-Cancer-MIBC/default.aspx

0 · Reply

Jaxtyn1989 May. 15 at 5:14 PM

$MDXH $GH $NTRA $PSNL Check $MDXH out, it has great potentials and analyst estimates to reach $5!

0 · Reply

JasonCO May. 15 at 2:44 PM

$NTRA scoop

0 · Reply

Market Cap	29.09B
Revenue (ttm)	2.31B
Net Income (ttm)	-208.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-9.03%
Debt to Equity Ratio	0.05

Volume	1,863,200
Avg Vol	1,442,556
Day's Range	N/A - N/A
Shares Out	143.22M
Stochastic %K	99%
Beta	1.57
Analysts	Strong Sell
Price Target	$259.72